Zobrazeno 1 - 10 of 146 pro vyhledávání: '"Noemí, Reguart"'
1
Akademický článek
Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
Autor: Ana Giménez‐Capitán, Estela Sánchez‐Herrero, Lucía Robado de Lope, Andrés Aguilar‐Hernández, Ivana Sullivan, Virginia Calvo, Irene Moya‐Horno, Santiago Viteri, Carlos Cabrera, Cristina Aguado, Noelia Armiger, Joselyn Valarezo, Clara Mayo‐de‐las‐Casas, Noemí Reguart, Rafael Rosell, Mariano Provencio, Atocha Romero, Miguel A. Molina‐Vila
Publikováno v: Molecular Oncology, Vol 17, Iss 9, Pp 1884-1897 (2023)
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material
Externí odkaz: https://doaj.org/article/895f32ea609d4f95922800c025292cd9
Zobrazit plný text záznamu
3
Akademický článek
Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
Autor: Diego Enrico, MD, Florencia Tsou, MD, Greta Catani, MD, Carmen Pupareli, MD, María Romina Girotti, PhD, David Esteban Ulloa Alvarez, MD, Federico Waisberg, MD, Andrés Rodríguez, MD, Roxana Reyes, MD, Matías Chacón, MD, Noemí Reguart, MD, PhD, Claudio Martín, MD
Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100456- (2023)
Limited strategies are available at disease progression on osimertinib for patients with EGFR-mutant NSCLC. The emergence of the on-target EGFR C797S mutation has been described as one of the most common mechanisms of resistance. In addition, loss of
Externí odkaz: https://doaj.org/article/4cf1881df756425180434e27468b9615
Zobrazit plný text záznamu
4
Akademický článek
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
Autor: Sergio Villatoro, Clara Mayo‐de‐las‐Casas, Núria Jordana‐Ariza, Santiago Viteri‐Ramírez, Mónica Garzón‐Ibañez, Irene Moya‐Horno, Beatriz García‐Peláez, María González‐Cao, Umberto Malapelle, Ariadna Balada‐Bel, Alejandro Martínez‐Bueno, Raquel Campos, Noemí Reguart, Margarita Majem, Remei Blanco, Ana Blasco, María J. Catalán, Xavier González, Giancarlo Troncone, Niki Karachaliou, Rafael Rosell, Miguel A. Molina‐Vila
Publikováno v: Molecular Oncology, Vol 13, Iss 12, Pp 2633-2645 (2019)
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations a
Externí odkaz: https://doaj.org/article/768780ab545245d49c5080fab9f9fe1b
Zobrazit plný text záznamu
5
Akademický článek
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
Autor: Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD
Publikováno v: JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100113- (2021)
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression. Olaparib was tested in co
Externí odkaz: https://doaj.org/article/08a2152e29af4e089606394482732718
Zobrazit plný text záznamu
6
Akademický článek
Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
Autor: José Manuel González de Aledo-Castillo, Samira Serhir-Sgheiri, Neus Calbet-Llopart, Ainara Arcocha, Pedro Jares, Noemí Reguart, Joan Antón Puig-Butillé
Publikováno v: Diagnostics, Vol 11, Iss 8, p 1319 (2021)
The cobas® EGFR Test provides a semiquantitative index (SQI) that reflects the proportion of mutated versus wild-type copies of the EGFR gene in plasma. The significance of SQI as an indirect measure of the variant allele frequency (VAF) or mutated
Externí odkaz: https://doaj.org/article/ab9a31a3f42d4c24b6ae8058e5954bbd
Zobrazit plný text záznamu
7
Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma
Autor: Paula Duch, Natalia Díaz-Valdivia, Rafael Ikemori, Marta Gabasa, Evette S. Radisky, Marselina Arshakyan, Sabrina Gea-Sorlí, Anna Mateu-Bosch, Paloma Bragado, Josep Lluís Carrasco, Hidetoshi Mori, Josep Ramírez, Cristina Teixidó, Noemí Reguart, Cristina Fillat, Derek C. Radisky, Jordi Alcaraz
Publikováno v: Matrix Biology. 111:207-225
Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an important regulator of extracellular matrix turnover that has been traditionally regarded as a potential tumor suppressor owing to its inhibitory effects of matrix metalloproteinases. Intriguingl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43154087079bd31b46b04a40bf5dc03d
https://doi.org/10.1016/j.matbio.2022.06.009
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje